Understanding the Use of Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase CML
Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses the reasons that the use of second-generation tyrosine kinase inhibitors in patients with chronic-phase CML who have failed one or more second-generation tyrosine kinase inhibitors needed further investigation.
Pharmacy Times® interviewed Hagop Kantarjian, MD, the professor and chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, on one of his presentations at the 62nd ASH Annual Meeting and Exposition. The presentation looks at the efficacy and safety of ponatinib in patients with chronic-phase chronic myeloid leukemia (CML) who failed one or more second-generation tyrosine kinase inhibitors.
In this video, Kantarjian explains the reasons that the use of second-generation tyrosine kinase inhibitors in patients with chronic-phase CML who have failed one or more second-generation tyrosine kinase inhibitors needed further investigation in the study, and what the lack of a durable response to treatment meant for the treatment opportunities available to these patients.
